MAPT and Alzheimer disease: Many studies have demonstrated potential biomarkers for AD conversion from prodromal stages, including amyloid-beta (Aβ) and tau proteins in cerebrospinal fluid (CSF), structural and functional neuroimaging features, and neuropsychological deficits in specific cognitive domains4–7.